Advancing Oncology and Immune-Oncology Therapeutic Development Using 3D Tumor Spheroids

Oncology is one of the fastest-moving therapeutic areas, which also makes it a highly competitive and complex space. Pharmaceutical companies are facing major challenges during early drug development due to the lack of optimal preclinical models for the evaluation of activity and safety, which lead to unsuccessful clinical trials.

In this webinar, Dr. Laure-Anne Ligeon and Dr Nils Goedecke from InSphero will highlight how over the last 15 years, the company has developed human-derived 3D in vitro tumor models that closely mimic the complexity and heterogeneity of the tumor microenvironment, while maintaining uniform composition and size between spheroids, enabling high scalability, reliability, and reproducibility.

The webinar will also delve into how 3D cancer models are used to evaluate the efficacy and the mechanism of action of promising anti-cancer drugs. Additionally, the speakers will demonstrate how InSphero’s 3D InSight™ Oncology platform unlocks a unique opportunity to determine the ability of therapeutic candidates to penetrate the tumor, providing reliable and physiologically relevant results for early-stage decisions.

Key learning objectives

• Discover the advantages of 3D human tumor spheroids over traditional 2D and animal testing in early drug development
• Learn how to select the right 3D tumor spheroids for your biological questions
• Gain insight into drug testing and readouts using complex 3D tumor models

Who should attend?

• Scientists from pharmaceutical and biotech companies and academia working in early oncology drug discovery.
• Scientists from pharmaceutical companies working on biosimilar development.
• Scientists working on research topics including CAR-T cells, therapeutic antibodies, ASO.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.